CL2022003147A1 - Composiciones y métodos para tratar pérdida auditiva asociada con gjb2 - Google Patents
Composiciones y métodos para tratar pérdida auditiva asociada con gjb2Info
- Publication number
- CL2022003147A1 CL2022003147A1 CL2022003147A CL2022003147A CL2022003147A1 CL 2022003147 A1 CL2022003147 A1 CL 2022003147A1 CL 2022003147 A CL2022003147 A CL 2022003147A CL 2022003147 A CL2022003147 A CL 2022003147A CL 2022003147 A1 CL2022003147 A1 CL 2022003147A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- hearing loss
- gjb2
- compositions
- loss associated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0082—Catheter tip comprising a tool
- A61M25/0084—Catheter tip comprising a tool being one or more injection needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M2025/0042—Microcatheters, cannula or the like having outside diameters around 1 mm or less
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0082—Catheter tip comprising a tool
- A61M25/0084—Catheter tip comprising a tool being one or more injection needles
- A61M2025/0093—Catheter tip comprising a tool being one or more injection needles wherein at least one needle is a microneedle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
Abstract
La presente invención proporciona constructos que comprenden una secuencia codificadora unida operativamente a un promotor, en donde la secuencia codificadora codifica una proteína conexina 26. Constructos ejemplares incluyen constructos de AAV. También se proporcionan métodos para usar los constructos divulgados para el tratamiento de pérdida auditiva y/o sordera.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063024468P | 2020-05-13 | 2020-05-13 | |
US202163152835P | 2021-02-23 | 2021-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022003147A1 true CL2022003147A1 (es) | 2023-07-21 |
Family
ID=78525016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022003147A CL2022003147A1 (es) | 2020-05-13 | 2022-11-11 | Composiciones y métodos para tratar pérdida auditiva asociada con gjb2 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230183743A1 (es) |
EP (1) | EP4164695A4 (es) |
JP (1) | JP2023526053A (es) |
KR (1) | KR20230023641A (es) |
CN (1) | CN116096900A (es) |
AU (1) | AU2021270308A1 (es) |
CA (1) | CA3178197A1 (es) |
CL (1) | CL2022003147A1 (es) |
IL (1) | IL298091A (es) |
MX (1) | MX2022014085A (es) |
WO (1) | WO2021231808A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023150689A2 (en) * | 2022-02-04 | 2023-08-10 | Decible Therapeutics, Inc. | Gjb2 regulatory elements and uses thereof |
CN116836975A (zh) * | 2022-03-25 | 2023-10-03 | 上海玮美基因科技有限责任公司 | 一种耳蜗和/或前庭细胞特异性启动子及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7387614B2 (en) * | 2003-08-26 | 2008-06-17 | University Of Maryland, Baltimore | Drug delivery to the inner ear and methods of using same |
CA2919140C (en) * | 2013-07-24 | 2018-05-01 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug |
SG10201913266UA (en) * | 2015-12-11 | 2020-02-27 | Massachusetts Eye & Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
WO2019200016A1 (en) * | 2018-04-10 | 2019-10-17 | President And Fellows Of Harvard College | Aav vectors encoding clarin-1 or gjb2 and uses thereof |
WO2020077295A1 (en) * | 2018-10-11 | 2020-04-16 | Decibel Therapeutics, Inc. | Aav1 vectors and uses thereof for treatment of otic indications |
EP3880826A4 (en) * | 2018-11-07 | 2022-08-24 | Akouos, Inc. | USE OF ADENO-ASSOCIATED VIRAL VECTORS TO CORRECT GENE DEFECTS/EXPRESS PROTEINS IN CILIATE AND SUPPORTING CELLS IN THE INNER EAR |
-
2021
- 2021-05-13 IL IL298091A patent/IL298091A/en unknown
- 2021-05-13 CN CN202180049197.6A patent/CN116096900A/zh active Pending
- 2021-05-13 JP JP2022568815A patent/JP2023526053A/ja active Pending
- 2021-05-13 AU AU2021270308A patent/AU2021270308A1/en active Pending
- 2021-05-13 WO PCT/US2021/032354 patent/WO2021231808A2/en unknown
- 2021-05-13 EP EP21803692.9A patent/EP4164695A4/en active Pending
- 2021-05-13 KR KR1020227043071A patent/KR20230023641A/ko active Search and Examination
- 2021-05-13 CA CA3178197A patent/CA3178197A1/en active Pending
- 2021-05-13 US US17/998,486 patent/US20230183743A1/en active Pending
- 2021-05-13 MX MX2022014085A patent/MX2022014085A/es unknown
-
2022
- 2022-11-11 CL CL2022003147A patent/CL2022003147A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20230023641A (ko) | 2023-02-17 |
WO2021231808A3 (en) | 2021-12-23 |
CN116096900A (zh) | 2023-05-09 |
JP2023526053A (ja) | 2023-06-20 |
EP4164695A4 (en) | 2024-06-05 |
EP4164695A2 (en) | 2023-04-19 |
WO2021231808A2 (en) | 2021-11-18 |
AU2021270308A1 (en) | 2022-12-15 |
US20230183743A1 (en) | 2023-06-15 |
IL298091A (en) | 2023-01-01 |
CA3178197A1 (en) | 2021-11-18 |
MX2022014085A (es) | 2022-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022003147A1 (es) | Composiciones y métodos para tratar pérdida auditiva asociada con gjb2 | |
PE20210114A1 (es) | .COMPOSICIONES DE ARNi CONTRA EL ANGIOTENSINOGENO (AGT) Y METODOS PARA SU USO | |
AR120534A1 (es) | Aislados paenibacillus y sus usos | |
CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
MX2021008131A (es) | Metodos y composiciones para el tratamiento de la enfermedad de fabry. | |
CL2020003190A1 (es) | Terapia génica cardíaca con aav para cardiomiopatía. | |
AR121390A1 (es) | Composiciones y métodos para tratar la deficiencia auditiva no relacionada con la edad en un sujeto humano | |
CL2022003153A1 (es) | Composiciones y métodos para tratar la pérdida auditiva asociada a slc26a4 | |
ECSP21087921A (es) | Materiales y métodos para modular la inmunidad mediada por células t | |
DOP2023000132A (es) | Composiciones y métodos para tratar la pérdida de audición y/o la pérdida de visión asociada a clrn1 | |
CL2020001494A1 (es) | Uso de una proteína no estructural de prv para proteger contra la inflamación del músculo esquelético y cardíaco. | |
ECSP23093588A (es) | Composiciones de suministro de terapia génica y métodos para tratar perdida auditiva | |
BR112023020490A2 (pt) | Composições e métodos para expressão de transgenes oculares | |
CO2022008738A2 (es) | Célula vectorial adyuvante artificial que contiene nyeso- 1 para uso en el tratamiento de cáncer | |
WO2022067340A3 (en) | Methods and compositions for the treatment of neurodegenerative diseases | |
CO2020008885A2 (es) | Arilsulfatasa a purificada y composiciones de la misma | |
ECSP23044970A (es) | Compuestos y composiciones de moléculas pequeñas | |
MX2021014028A (es) | Métodos y composiciones para tratar obesidad y/o trastornos de la piel. | |
AR120198A1 (es) | Construcciones de variantes de igf2 | |
CL2023003387A1 (es) | Composición cosmética, para prevención y/o tratamiento de señales resultantes del envejecimiento de la piel | |
CO2022003324A2 (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares | |
ECSP22020678A (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares | |
AR128239A1 (es) | Composiciones y métodos útiles para el tratamiento de trastornos mediados por c9orf72 | |
EA202092654A1 (ru) | Генная терапия сердца с помощью aav при кардиомиопатии | |
AR116493A1 (es) | Composiciones y métodos para tratar la retinosis pigmentaria |